These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20015594)

  • 21. Bone directed therapies for prostate cancer.
    Bradley DA; Hussain M; Dipaola RS; Kantoff P
    J Urol; 2007 Sep; 178(3 Pt 2):S42-8. PubMed ID: 17644119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
    Shakespeare WC; Metcalf CA; Wang Y; Sundaramoorthi R; Keenan T; Weigele M; Bohacek RS; Dalgarno DC; Sawyer TK
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):729-41. PubMed ID: 14579523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
    Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
    J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
    Vessella RL; Corey E
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers.
    Waltregny D; Bellahcène A; de Leval X; Florkin B; Weidle U; Castronovo V
    J Bone Miner Res; 2000 May; 15(5):834-43. PubMed ID: 10804012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
    Chirgwin JM; Guise TA
    Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone targeted therapies in metastatic castration-resistant prostate cancer.
    Rajpar S; Fizazi K
    Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
    Russell MR; Jamieson WL; Dolloff NG; Fatatis A
    Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SRC inhibitors in metastatic bone disease.
    Boyce BF; Xing L; Yao Z; Yamashita T; Shakespeare WC; Wang Y; Metcalf CA; Sundaramoorthi R; Dalgarno DC; Iuliucci JD; Sawyer TK
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6291s-6295s. PubMed ID: 17062716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
    Tan M; Li P; Sun M; Yin G; Yu D
    Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. c-Src expression is predictive of poor prognosis in breast cancer patients with bone metastasis, but not in patients with visceral metastasis.
    Zhang L; Teng Y; Zhang Y; Liu J; Xu L; Qu J; Hou K; Yang X; Liu Y; Qu X
    APMIS; 2012 Jul; 120(7):549-57. PubMed ID: 22716210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of therapeutic agents to bone to treat metastatic cancer.
    Bagi CM
    Adv Drug Deliv Rev; 2005 May; 57(7):995-1010. PubMed ID: 15876400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
    Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
    Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
    Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
    Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.
    van der Pluijm G; Sijmons B; Vloedgraven H; Deckers M; Papapoulos S; Löwik C
    J Bone Miner Res; 2001 Jun; 16(6):1077-91. PubMed ID: 11393785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone metastases in prostate cancer: a targeted approach.
    Storey JA; Torti FM
    Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
    Hiraga T; Myoui A; Choi ME; Yoshikawa H; Yoneda T
    Cancer Res; 2006 Feb; 66(4):2067-73. PubMed ID: 16489006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
    Hannon RA; Finkelman RD; Clack G; Iacona RB; Rimmer M; Gossiel F; Baselga J; Eastell R
    Bone; 2012 Apr; 50(4):885-92. PubMed ID: 22245630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.